- Investing.com
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Metrics to compare | PHAR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHARPeersSector | |
---|---|---|---|---|
P/E Ratio | −48.9x | −3.5x | −0.5x | |
PEG Ratio | 4.30 | 0.00 | 0.00 | |
Price / Book | 2.6x | 2.7x | 2.6x | |
Price / LTM Sales | 2.0x | 10.3x | 2.9x | |
Upside (Analyst Target) | 160.7% | 276.3% | 64.0% | |
Fair Value Upside | Unlock | 7.6% | 9.4% | Unlock |